Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management.
作者信息
Mehta Neil
机构信息
Division of Gastroenterology Department of Medicine University of California, San Francisco San Francisco CA.
出版信息
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):332-336. doi: 10.1002/cld.1054. eCollection 2021 May.
Abstract
摘要
相似文献
1
Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management.肝细胞癌的肝移植标准，包括移植后管理。
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):332-336. doi: 10.1002/cld.1054. eCollection 2021 May.
2
Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation.肝移植前肝细胞癌降期的当前方法。
Curr Opin Organ Transplant. 2008 Jun;13(3):234-40. doi: 10.1097/MOT.0b013e3282fc2633.
3
Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.血清甲胎蛋白水平独立预测肝癌患者移植后的生存情况。
Liver Transpl. 2013 Jun;19(6):634-45. doi: 10.1002/lt.23652.
4
A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.索拉非尼治疗肝移植前肝细胞癌的前瞻性临床试验。
BMC Cancer. 2019 Jun 11;19(1):568. doi: 10.1186/s12885-019-5760-8.
5
Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma.新辅助经动脉化疗栓塞术可提高肝细胞癌患者肝移植后的生存率。
Exp Clin Transplant. 2019 Oct;17(5):638-643. doi: 10.6002/ect.2018.0017. Epub 2018 Sep 25.
6
Liver transplantation: an update 2008.肝移植：2008年最新进展
Curr Opin Gastroenterol. 2008 May;24(3):339-45. doi: 10.1097/MOG.0b013e3282f8e27e.
7
Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.第 3 节：肝移植前肝癌降期的现状。
Transplantation. 2014 Apr 27;97 Suppl 8:S10-7. doi: 10.1097/01.tp.0000446267.19148.21.
8
More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma.不仅仅是等待时间？肝细胞癌肝移植结局的区域性差异。
Transplantation. 2019 Apr;103(4):747-754. doi: 10.1097/TP.0000000000002248.
9
Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria.超出米兰标准的肝细胞癌肝移植
Exp Clin Transplant. 2017 Mar;15(Suppl 2):59-64. doi: 10.6002/ect.TOND16.L16.
10
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.索拉非尼在肝移植术后复发性肝细胞癌患者中的作用。
Prog Transplant. 2016 Dec;26(4):348-355. doi: 10.1177/1526924816664083. Epub 2016 Sep 20.
引用本文的文献
1
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric.肝细胞癌患者肝移植选择标准的预后作用：综述与文献计量学分析
ILIVER. 2024 Feb 6;3(1):100077. doi: 10.1016/j.iliver.2024.100077. eCollection 2024 Mar.
2
Liver transplantation for malignant liver tumors.恶性肝肿瘤的肝移植
ILIVER. 2022 Apr 18;1(1):3-11. doi: 10.1016/j.iliver.2022.04.002. eCollection 2022 Mar.
3
HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity.HepatoPredict可准确筛选出适合肝移植的肝细胞癌患者，无论肿瘤的异质性如何。
Cancers (Basel). 2025 Feb 2;17(3):500. doi: 10.3390/cancers17030500.
4
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.肝移植前肝细胞癌降期：一项全国多中心前瞻性队列研究的结果
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231.
5
The effectiveness of exercise prehabilitation on aerobic capacity, muscle strength and body composition in patients with cirrhosis awaiting liver transplantation: a systematic review and meta-analysis protocol.运动康复对等待肝移植的肝硬化患者有氧能力、肌肉力量和身体成分的影响：系统评价和荟萃分析方案。
Syst Rev. 2024 Sep 3;13(1):225. doi: 10.1186/s13643-024-02608-y.
6
Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation.用于评估肝移植前肝细胞癌预后的HepatoPredict试剂盒的分析验证及算法改进。
Pract Lab Med. 2024 Feb 5;39:e00365. doi: 10.1016/j.plabm.2024.e00365. eCollection 2024 Mar.
7
Effects of Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus.基因型对接受他克莫司治疗的肝移植患者血小板减少症的影响。
Biomedicines. 2023 Nov 17;11(11):3088. doi: 10.3390/biomedicines11113088.
8
HiCCups in management-Pitfalls and pearls for the management of HCC.肝癌管理中的HiCCups——肝癌管理的陷阱与要点
Clin Liver Dis (Hoboken). 2023 May 10;22(3):85-88. doi: 10.1097/CLD.0000000000000041. eCollection 2023 Sep.
9
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.免疫疗法与肝移植：基础与临床数据的叙述性综述
Cancers (Basel). 2023 Sep 15;15(18):4574. doi: 10.3390/cancers15184574.
10
Liver Transplantation: Protocol for Recipient Selection, Evaluation, and Assessment.肝移植：受体选择、评估与评定方案
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):841-853. doi: 10.1016/j.jceh.2023.04.002. Epub 2023 Apr 17.
本文引用的文献
1
National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.国家在肝移植前对肝细胞癌降期的经验：肿瘤负担、甲胎蛋白和等待时间的影响。
Hepatology. 2020 Mar;71(3):943-954. doi: 10.1002/hep.30879. Epub 2019 Oct 15.
2
What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?肝细胞癌的最佳肝移植标准是什么？
Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):20-25. doi: 10.1002/cld.793. eCollection 2019 Jan.
3
Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.长等待时间地区肝癌肝移植候补名单中低辍学风险的预测因素：对器官分配的影响。
Am J Transplant. 2019 Aug;19(8):2210-2218. doi: 10.1111/ajt.15353. Epub 2019 Apr 5.
4
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.利用 UNOS 数据库验证 RETREAT 评分对肝细胞癌复发预后的预测能力。
Am J Transplant. 2018 May;18(5):1206-1213. doi: 10.1111/ajt.14549. Epub 2017 Dec 2.
5
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.Metroticket 2.0 模型分析肝癌肝移植术后死亡的竞争风险。
Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5.
6
Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer.肝移植治疗肝细胞癌患者的意向治疗生存获益。
Hepatology. 2017 Dec;66(6):1910-1919. doi: 10.1002/hep.29342. Epub 2017 Nov 6.
7
Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.肝细胞癌肝移植后的复发：故事的新寓意。
Ann Surg. 2017 Mar;265(3):557-564. doi: 10.1097/SLA.0000000000001966.
8
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.西罗莫司在肝细胞癌肝移植受者中的应用：一项随机、多中心、开放标签的3期试验。
Transplantation. 2016 Jan;100(1):116-25. doi: 10.1097/TP.0000000000000965.
9
Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.降低肝细胞癌分期：一项系统评价与汇总分析
Liver Transpl. 2015 Sep;21(9):1142-52. doi: 10.1002/lt.24169.
10
Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.肝移植前肝细胞癌降期：与米兰标准内肿瘤相比的长期预后
Hepatology. 2015 Jun;61(6):1968-77. doi: 10.1002/hep.27752. Epub 2015 Mar 20.
Zotero 插件